Sugi Predict

Sugi Predict / Targets / CYP3A5

CYP3A5

Cytochrome P450 3A5 · P20815 · CYP3A5 on Sugi Atlas →

57,633 patent compounds predicted against CYP3A5, 41,602 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Telithromycin Telithromycin (SCHEMBL5100) 1.00 6/20
Telithromycin Telithromycin (SCHEMBL5101) 1.00 6/20
SCHEMBL323776 SCHEMBL323776 0.61 6/20
Purine Purine (SCHEMBL289483) 0.46 5/20
SCHEMBL210120 SCHEMBL210120 0.61 4/20
Triarimol Triarimol (SCHEMBL149650) 0.55 4/20
SCHEMBL13577 SCHEMBL13577 0.53 3/20
SCHEMBL323982 SCHEMBL323982 0.41 3/20
Bufalin Bufalin (SCHEMBL165666) 1.00 2/20
SCHEMBL43956 SCHEMBL43956 0.93 2/20
SCHEMBL43957 SCHEMBL43957 0.93 2/20
SCHEMBL84978 SCHEMBL84978 0.84 2/20
SCHEMBL84543 SCHEMBL84543 0.79 2/20
Fenarimol Fenarimol (SCHEMBL42209) 0.74 2/20
SCHEMBL196765 SCHEMBL196765 0.73 2/20
Bufogenin Bufogenin (SCHEMBL309405) 0.72 2/20
Bufogenin Bufogenin (SCHEMBL309406) 0.72 2/20
SCHEMBL84929 SCHEMBL84929 0.70 2/20
SCHEMBL84985 SCHEMBL84985 0.70 2/20
SCHEMBL85532 SCHEMBL85532 0.69 2/20

Clinical trials — most relevant to CYP3A5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Utilising Genotype Informed Bayesian Dosing of Tacrolimus in Children Post Solid Organ Transplantation. PHASE4RECRUITING
Physiological Study of the Human CYP3A Activity (PiSA) PHASE4COMPLETED
Study of HS-20105 for Injection in Patients With Advanced Solid Tumors. PHASE1/PHASE2NOT_YET_RECRUITING
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma PHASE2NOT_YET_RECRUITING
APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma PHASE1/PHASE2UNKNOWN
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial PHASE2ACTIVE_NOT_RECRUITING
Evaluation of the Effect of Multiple Dosing With BI 201335 on CYP2B6 Metabolism and Effect of Multiple Dosing With Efavirenz on the Steady-state Pharmacokinetics of BI 201335 and on CYP3A4/5 Metabolism in Healthy Volunteers PHASE1COMPLETED
The Effect of CYP3A Genetic Polymorphism on the Pharmacokinetics of Phosphodiesterase type5 Inhibitors in Male Subjects PHASE1COMPLETED
Polymorphic Effects of Cytochrome P450 3A5 on Pharmacokinetics of Maraviroc and Its Metabolites PHASE1COMPLETED
Study of HL-085 in Patients With Advanced Solid Tumor Tumors PHASE1COMPLETED
The Influence of Phenotype, Grapefruit Juice and Orange Juice on the Pharmacokinetics of Sunitinib in Cancer Patients PHASE1COMPLETED
A Phase 1, Multiple Ascending Dose Study to Evaluate HMS1005 in Participants With Type 2 Diabetes PHASE1RECRUITING
TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects. PHASE1COMPLETED
Effect of Dexamethasone on CYP Enzyme Activity in Healthy Male Subjects PHASE1NOT_YET_RECRUITING
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer PHASE1COMPLETED
Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite PHASE1COMPLETED
Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors PHASE1UNKNOWN
Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS) PHASE1COMPLETED
A Study of CS3005 in Advanced Solid Tumors PHASE1COMPLETED
A Phase 0 Study of AZD1775 in Recurrent GBM Patients EARLY_PHASE1COMPLETED
BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors EARLY_PHASE1RECRUITING
Metabolism of Chlordiazepoxide in the Treatment of Alcohol Withdrawal Symptoms nanCOMPLETED
Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients nanCOMPLETED
Evaluation of Pharmacogenetic Factors Affecting Fentanyl Requirements for Postoperative Pain Control nanCOMPLETED
Pharmacogenomics of New Antiretrovirals nanCOMPLETED
Renal Function and Pharmacogenetics in Renal Transplant Recipients Converted From Tac BID to Tac OD nanCOMPLETED
Determinants of Immunosuppressive Dose Requirements in Children After Solid Organ Transplantation nanCOMPLETED
Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients nanCOMPLETED
Analysis of the Effect of Donor CYP3A5 Gene Polymorphism on Early Tacrolimus Concentration and Postoperative Acute Renal Injury After Liver Transplantation nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CYP3A5 binder may also engage these)

ProteinNameSimilarity
CYP3A7 Cytochrome P450 3A7 1.000 landscape →
O18993 — 1.000 O18993 →
P79401 — 1.000 P79401 →
Q64464 — 1.000 Q64464 →
Q29496 — 1.000 Q29496 →
P33268 — 1.000 P33268 →
P24463 — 1.000 P24463 →
Q8AXY5 — 0.999 Q8AXY5 →
O09158 — 0.999 O09158 →
P11707 — 0.999 P11707 →
Q64481 — 0.999 Q64481 →
Q64459 — 0.998 Q64459 →
P79102 — 0.998 P79102 →
CYP3A4 Cytochrome P450 3A4 0.998 landscape →
P05183 — 0.997 P05183 →
Q9PVE8 — 0.996 Q9PVE8 →
P51538 — 0.996 P51538 →
Q64581 — 0.995 Q64581 →
Q98T91 — 0.994 Q98T91 →
P04800 — 0.994 P04800 →
Q64406 — 0.994 Q64406 →
O42563 — 0.992 O42563 →
Q64417 — 0.992 Q64417 →
O70537 — 0.990 O70537 →
CYP3A43 Cytochrome P450 3A43 0.989 landscape →
Q64148 — 0.989 Q64148 →
Q64409 — 0.989 Q64409 →
Q9JMA7 — 0.987 Q9JMA7 →
Q964R0 — 0.980 Q964R0 →
P24464 — 0.980 P24464 →